These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27912831)

  • 1. Systemic Treatment of Brain Metastases.
    Waqar SN; Morgensztern D; Govindan R
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):157-176. PubMed ID: 27912831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
    Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
    Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC; Neal JW; Niu XM; Wakelee HA
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
    Klempner SJ; Ou SH
    Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer.
    Baik CS; Chamberlain MC; Chow LQ
    J Thorac Oncol; 2015 Sep; 10(9):1268-1278. PubMed ID: 26107553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
    Zhang I; Zaorsky NG; Palmer JD; Mehra R; Lu B
    Lancet Oncol; 2015 Oct; 16(13):e510-21. PubMed ID: 26433824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutation status on brain metastases from non-small cell lung cancer.
    Hsu F; De Caluwe A; Anderson D; Nichol A; Toriumi T; Ho C
    Lung Cancer; 2016 Jun; 96():101-7. PubMed ID: 27133758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
    J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer.
    Bulbul A; Forde PM; Murtuza A; Woodward B; Yang H; Bastian I; Ferguson PK; Lopez-Diaz F; Ettinger DS; Husain H
    Oncology (Williston Park); 2018 Apr; 32(4):156-63. PubMed ID: 29684234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
    Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
    J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.
    Khandekar MJ; Piotrowska Z; Willers H; Sequist LV
    Oncologist; 2018 Sep; 23(9):1054-1062. PubMed ID: 29703765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapy in Brain Metastases: Ready for Primetime?
    Venur VA; Ahluwalia MS
    Am Soc Clin Oncol Educ Book; 2016; 35():e123-30. PubMed ID: 27249714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.
    Li DL; Chen XR; Ma SX; Chen LK
    Thorac Cancer; 2016 Sep; 7(5):619-622. PubMed ID: 27766783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
    Wardak Z; Choy H
    J Clin Oncol; 2016 Dec; 34(34):4064-4065. PubMed ID: 27863198
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.